Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma

NAVIGATOR PRIMARY ENDPOINTS2 | ||
Endpoint | Timepoint | Results Tezepelumab added to SoC vs placebo added to SoC |
AAER ? overall patient population | Over 52 weeks | 56% reduction* (95% CI: 47, 63; p<0.001) |
AAER ? baseline eosinophil counts < 300 cells/?L | Over 52 weeks | 41% reduction* (95% CI: 25, 54; p<0.001) |
CI: confidence interval |
- Bonini M, Di Paolo M, Bagnasco D,?et al.?Minimal clinically important difference for asthma endpoints: an expert consensus report.?Eur Respir Rev. 2020; 29: 190137.
- Menzies-Gow A, Corre J, Bourdin A,?et al. Efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study. L 46. AAAAI poster.?February 2021.
- Corren J, Parnes JR, Wang L,?et al. Tezepelumab in Adults with Uncontrolled Asthma [published correction appears in?N Engl J Med. 2019 May 23; 380 (21): 2082].?N Engl J Med. 2017; 377 (10): 936-946.
- Wenzel S, Castro M, Corren J,?et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ?2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.?Lancet. 2016;388 (10039): 31-44.
- Castro M, Corren J, Pavord I.D,?et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.?N Engl J Med?2018; 378:2486-2496.
- Bleecker ER, FitzGerald JM, Chanez P,?et al, on behalf of the SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.?Lancet?2016: 388 (10056): 2115-2127.
- 7.? FitzGerald JM, Bleecker ER, Nair P,?et al, on behalf of the CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.?Lancet?2016: 388(10056): 2128-2141.
- FitzGerald JM, Bleecker ER, Menzies-Gow A,?et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.?Lancet Respir Med. 2018; 6 (1): 51-64.
- Varricchi G, Pecoraro A, Marone G,?et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer.?Front Immunol. 2018; 9: 1595.
- Ortega HG, Liu MC, Pavord ID,?et al; on behalf of the MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma.?N Engl J Med. 2014;371(13):1198-207.
- Kupczyk M, Wenzel S. U.S. and European severe asthma cohorts: what can they teach us about severe asthma??J Intern Med?2012;272:121?32.
- Wenzel S. Severe Asthma in Adults.?Am J Respir Crit Care Med. 2005; 172; 149?60.
- Chung KF, Wenzel SE, Brozek JL,?et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.?Eur Respir J. 2014; 43: 343?73.
- Price D, Fletcher M,?van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey.?NPJ Prim Care Respir Med. 2014; 12; 24: 14009.
- World Allergy Organization?(WAO). The management of severe asthma: economic analysis of the cost of treatments for severe asthma. Available at:?https://www.worldallergy.org/educational_programs/world_allergy_forum/anaheim2005/blaiss.php?[Last accessed:?February 2021].
- Busse WW. Biological Treatments for Severe Asthma: A Major Advance in Asthma Care.?Allergol Int?2019; 68: 158?66.
- Godar M, Blanchetot C, de Haard H,?et al. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.?MAbs. 2018; 10 (1): 34?45.
- Rabe KF, Busse W, Pavord I, Castro M. Raising the clinical bar beyond current biologics in uncontrolled persistent asthma: translating emerging data in future clinical decisions.?EMJ Allergy Immunol. 2018; 3: 60-9.
- Peters MC, Mekonnen ZK, Yuan S,?et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.?J Allergy Clin Immunol. 2014; 133: 388?94.
- Clinicaltrials.gov. Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent?Asthma?(SOURCE) [Online]. Available at:?https://clinicaltrials.gov/ct2/show/NCT03406078. [Last accessed:?February 2021].
- Fahy JV. Type 2 inflammation in asthma--present in most, absent in many.?Nat Rev Immunol. 2015; 15: 57-65.
- Roseti S, Corren J, Parnes JR,?et al. Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study.?European Respiratory Journal?2017; 50: OA3189.
- Wechsler, M.E., Colice, G., Griffiths, J.M.?et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.?Respir Res?2020; 21: 264.
- Clinicaltrials.gov. Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (NAVIGATOR) [Online]. Available at:?https://clinicaltrials.gov/ct2/show/NCT03347279. [Last accessed:?February 2021].
- AstraZeneca plc. Tezepelumab NAVIGATOR Phase III trial met primary endpoint of a statistically significant and clinically meaningful reduction in exacerbations in a broad population of patients with severe asthma. Available at:?https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/tezepelumab-navigator-phase-iii-trial-met-primary-endpoint.html.?[Last accessed:?February 2021].
- Clinicaltrials.gov. Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (DESTINATION) [Online]. Available at:?https://clinicaltrials.gov/ct2/show/NCT03706079. [Last accessed:?February 2021].